We thus hypothesized that augmenting SSTR1 expression or SSTR1 signaling (e.g., using an agonist) may suppress tumor growth and serve as a therapeutic avenue for ARSI-resistant PCa. This evidence concerns the gene SSTR1 and posterior cortical atrophy.